International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

@article{Dombret2015InternationalP3,
  title={International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.},
  author={Herv{\'e} Dombret and John F Seymour and Aleksandra Butrym and Agnieszka Wierzbowska and Dominik L D Selleslag and Jun Ho Jang and R. Pradeep Kumar and James D. Cavenagh and Andre C. Schuh and Anna Candoni and Christian R{\'e}cher and Irwindeep Sandhu and Teresa Bernal del Castillo and Haifa Kathrin Al-Ali and Giovanni Martinelli and Jose Francisco Falantes and Richard Noppeney and Richard M Stone and Mark D Minden and Heidi J McIntyre and Steve Songer and Lela M Lucy and C L Beach and Hartmut D{\"o}hner},
  journal={Blood},
  year={2015},
  volume={126 3},
  pages={291-9}
}
This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and safety vs conventional care regimens (CCRs) in 488 patients age ≥65 years with newly diagnosed acute myeloid leukemia (AML) with >30% bone marrow blasts. Before randomization, a CCR (standard induction chemotherapy, low-dose ara-c, or supportive care only) was preselected for each patient. Patients then were assigned 1:1 to azacitidine (n = 241) or CCR (n = 247). Patients assigned to CCR received their… CONTINUE READING